GL Pharm Tech Balance Sheet Health
Financial Health criteria checks 6/6
GL Pharm Tech has a total shareholder equity of ₩20.3B and total debt of ₩16.6B, which brings its debt-to-equity ratio to 81.8%. Its total assets and total liabilities are ₩46.7B and ₩26.3B respectively.
Key information
81.8%
Debt to equity ratio
₩16.62b
Debt
Interest coverage ratio | n/a |
Cash | ₩12.13b |
Equity | ₩20.33b |
Total liabilities | ₩26.33b |
Total assets | ₩46.66b |
Recent financial health updates
Is GL Pharm Tech (KOSDAQ:204840) A Risky Investment?
Jul 23Would GL Pharm Tech (KOSDAQ:204840) Be Better Off With Less Debt?
Mar 30Recent updates
Is GL Pharm Tech (KOSDAQ:204840) A Risky Investment?
Jul 23Market Participants Recognise GL Pharm Tech Corp.'s (KOSDAQ:204840) Revenues Pushing Shares 25% Higher
Mar 01Would GL Pharm Tech (KOSDAQ:204840) Be Better Off With Less Debt?
Mar 30The GL Pharm Tech (KOSDAQ:204840) Share Price Is Up 50% And Shareholders Are Holding On
Dec 15Financial Position Analysis
Short Term Liabilities: A204840's short term assets (₩23.6B) exceed its short term liabilities (₩16.8B).
Long Term Liabilities: A204840's short term assets (₩23.6B) exceed its long term liabilities (₩9.5B).
Debt to Equity History and Analysis
Debt Level: A204840's net debt to equity ratio (22.1%) is considered satisfactory.
Reducing Debt: A204840's debt to equity ratio has reduced from 187.8% to 81.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A204840 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A204840 has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 1.5% each year.